31 results
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
persistence. Importantly, there were no cases of relapse due to antigen-negative escape, with a median follow-up of 8.7 months. Overall survival was 75% at 6 … on cancer cells. Studies have shown that tumors develop escape mechanisms that prevent T cell-mediated destruction through immune checkpoint proteins
8-K/A
EX-99.1
AUTL
Autolus Therapeutics plc
15 Mar 24
Results of Operations and Financial Condition
4:21pm
a loss of CD19 antigen as of right of escape. And that's certainly shown in ALL. It's clearly shown in obe-cel. So there's a very clear kind of directions
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
package Dual CD19 & CD22 Targeting Designed to prevent antigen negative escape Supported by Phase 1 data in pediatric B-ALL Dual CD19 & BCMA Targeting
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
13 Feb 24
Regulation FD Disclosure
4:06pm
to prevent antigen negative escape Supported by Phase 1 data in pediatric B-ALL Dual CD19 & BCMA Targeting Designed to induce deep and durable … of leukemic relapse or emergence of MRD related to antigen escape Ghorashian et al., EBMT Annual Meeting 2023 CARPALL Disease Response (n=12) ALLCAR19 Adult ALL
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
11 Dec 23
Regulation FD Disclosure
8:31am
negative escape Supported by Phase 1 data in pediatric B-ALL B-ALL and B-NHLAUTO1/22 CD19/CD22 Dual CD19 & BCMA Targeting Designed to induce deep
10-Q
EX-10.1
9i1msd
9 Nov 23
Quarterly report
4:18pm
424B5
ha69acba40u5ibkley
9 Dec 22
Prospectus supplement for primary offering
5:40pm
424B5
pve 8fm4fvkxr18ulgj
8 Dec 22
Prospectus supplement for primary offering
4:10pm
424B5
j69d56g 04
19 Aug 21
Prospectus supplement for primary offering
4:13pm
F-3
3yr f5jelufn
6 Aug 21
Shelf registration (foreign)
2:30pm
6-K
EX-1
r3t6o
30 Jun 21
Annual Report and Accounts
6:05am
424B5
9dhwxs
11 Feb 21
Prospectus supplement for primary offering
5:16pm
424B5
bw108l
8 Feb 21
Prospectus supplement for primary offering
5:27pm
424B5
83drg
18 Sep 20
Prospectus supplement for primary offering
8:01am
6-K
EX-1
murb0ms8b5l
26 May 20
Current report (foreign)
4:31pm
424B5
hb9vl6qnno8 vgiu9
24 Jan 20
Prospectus supplement for primary offering
4:11pm
424B5
uapqo xhnuik
22 Jan 20
Prospectus supplement for primary offering
5:30pm